Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer

Alex J. Walsh, Rebecca S. Cook, H. Charles Manning, Donna J. Hicks, Alec Lafontant, Carlos L. Arteaga, Melissa C. Skala

Research output: Contribution to journalArticle

140 Citations (Scopus)

Abstract

Abnormal cellular metabolism is a hallmark of cancer, yet there is an absence of quantitative methods to dynamically image this powerful cellular function. Optical metabolic imaging (OMI) is a noninvasive, highresolution, quantitative tool for monitoring cellular metabolism. OMI probes the fluorescence intensities and lifetimes of the autofluorescent metabolic coenzymes reduced NADH and flavin adenine dinucleotide. We confirm that OMI correlates with cellular glycolytic levels across a panel of human breast cell lines using standard assays of cellular rates of glucose uptake and lactate secretion (P < 0.05, r = 0.89). In addition, OMI resolves differences in the basal metabolic activity of untransformed from malignant breast cells (P < 0.05) and between breast cancer subtypes (P< 0.05), defined by estrogen receptor and/or HER2 expression or absence. In vivo OMI is sensitive to metabolic changes induced by inhibition of HER2 with the antibody trastuzumab (herceptin) in HER2-overexpressing human breast cancer xenografts in mice. This response was confirmed with tumor growth curves and stains for Ki67 and cleaved caspase-3. OMI resolved trastuzumab-induced changes in cellular metabolism in vivo as early as 48 hours posttreatment (P < 0.05), whereas fluorodeoxyglucose-positron emission tomography did not resolve any changes with trastuzumab up to 12 days posttreatment (P > 0.05). In addition, OMI resolved cellular subpopulations of differing response in vivo that are critical for investigating drug resistance mechanisms. Importantly, OMI endpoints remained unchanged with trastuzumab treatment in trastuzumabresistant xenografts (P > 0.05). OMI has significant implications for rapid cellular-level assessment of metabolic response to molecular expression and drug action, which would greatly accelerate drug development studies.

Original languageEnglish (US)
Pages (from-to)6164-6174
Number of pages11
JournalCancer Research
Volume73
Issue number20
DOIs
StatePublished - Oct 15 2013

Fingerprint

Optical Imaging
Breast Neoplasms
Flavin-Adenine Dinucleotide
Coenzymes
Drug Resistance
Heterografts
Pharmaceutical Preparations
NAD
Lactic Acid
Breast
Fluorescence
Glucose
Cell Line
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer. / Walsh, Alex J.; Cook, Rebecca S.; Manning, H. Charles; Hicks, Donna J.; Lafontant, Alec; Arteaga, Carlos L.; Skala, Melissa C.

In: Cancer Research, Vol. 73, No. 20, 15.10.2013, p. 6164-6174.

Research output: Contribution to journalArticle

Walsh, Alex J. ; Cook, Rebecca S. ; Manning, H. Charles ; Hicks, Donna J. ; Lafontant, Alec ; Arteaga, Carlos L. ; Skala, Melissa C. / Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer. In: Cancer Research. 2013 ; Vol. 73, No. 20. pp. 6164-6174.
@article{1623307a3069497ab31103b9c2db69fd,
title = "Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer",
abstract = "Abnormal cellular metabolism is a hallmark of cancer, yet there is an absence of quantitative methods to dynamically image this powerful cellular function. Optical metabolic imaging (OMI) is a noninvasive, highresolution, quantitative tool for monitoring cellular metabolism. OMI probes the fluorescence intensities and lifetimes of the autofluorescent metabolic coenzymes reduced NADH and flavin adenine dinucleotide. We confirm that OMI correlates with cellular glycolytic levels across a panel of human breast cell lines using standard assays of cellular rates of glucose uptake and lactate secretion (P < 0.05, r = 0.89). In addition, OMI resolves differences in the basal metabolic activity of untransformed from malignant breast cells (P < 0.05) and between breast cancer subtypes (P< 0.05), defined by estrogen receptor and/or HER2 expression or absence. In vivo OMI is sensitive to metabolic changes induced by inhibition of HER2 with the antibody trastuzumab (herceptin) in HER2-overexpressing human breast cancer xenografts in mice. This response was confirmed with tumor growth curves and stains for Ki67 and cleaved caspase-3. OMI resolved trastuzumab-induced changes in cellular metabolism in vivo as early as 48 hours posttreatment (P < 0.05), whereas fluorodeoxyglucose-positron emission tomography did not resolve any changes with trastuzumab up to 12 days posttreatment (P > 0.05). In addition, OMI resolved cellular subpopulations of differing response in vivo that are critical for investigating drug resistance mechanisms. Importantly, OMI endpoints remained unchanged with trastuzumab treatment in trastuzumabresistant xenografts (P > 0.05). OMI has significant implications for rapid cellular-level assessment of metabolic response to molecular expression and drug action, which would greatly accelerate drug development studies.",
author = "Walsh, {Alex J.} and Cook, {Rebecca S.} and Manning, {H. Charles} and Hicks, {Donna J.} and Alec Lafontant and Arteaga, {Carlos L.} and Skala, {Melissa C.}",
year = "2013",
month = "10",
day = "15",
doi = "10.1158/0008-5472.CAN-13-0527",
language = "English (US)",
volume = "73",
pages = "6164--6174",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer

AU - Walsh, Alex J.

AU - Cook, Rebecca S.

AU - Manning, H. Charles

AU - Hicks, Donna J.

AU - Lafontant, Alec

AU - Arteaga, Carlos L.

AU - Skala, Melissa C.

PY - 2013/10/15

Y1 - 2013/10/15

N2 - Abnormal cellular metabolism is a hallmark of cancer, yet there is an absence of quantitative methods to dynamically image this powerful cellular function. Optical metabolic imaging (OMI) is a noninvasive, highresolution, quantitative tool for monitoring cellular metabolism. OMI probes the fluorescence intensities and lifetimes of the autofluorescent metabolic coenzymes reduced NADH and flavin adenine dinucleotide. We confirm that OMI correlates with cellular glycolytic levels across a panel of human breast cell lines using standard assays of cellular rates of glucose uptake and lactate secretion (P < 0.05, r = 0.89). In addition, OMI resolves differences in the basal metabolic activity of untransformed from malignant breast cells (P < 0.05) and between breast cancer subtypes (P< 0.05), defined by estrogen receptor and/or HER2 expression or absence. In vivo OMI is sensitive to metabolic changes induced by inhibition of HER2 with the antibody trastuzumab (herceptin) in HER2-overexpressing human breast cancer xenografts in mice. This response was confirmed with tumor growth curves and stains for Ki67 and cleaved caspase-3. OMI resolved trastuzumab-induced changes in cellular metabolism in vivo as early as 48 hours posttreatment (P < 0.05), whereas fluorodeoxyglucose-positron emission tomography did not resolve any changes with trastuzumab up to 12 days posttreatment (P > 0.05). In addition, OMI resolved cellular subpopulations of differing response in vivo that are critical for investigating drug resistance mechanisms. Importantly, OMI endpoints remained unchanged with trastuzumab treatment in trastuzumabresistant xenografts (P > 0.05). OMI has significant implications for rapid cellular-level assessment of metabolic response to molecular expression and drug action, which would greatly accelerate drug development studies.

AB - Abnormal cellular metabolism is a hallmark of cancer, yet there is an absence of quantitative methods to dynamically image this powerful cellular function. Optical metabolic imaging (OMI) is a noninvasive, highresolution, quantitative tool for monitoring cellular metabolism. OMI probes the fluorescence intensities and lifetimes of the autofluorescent metabolic coenzymes reduced NADH and flavin adenine dinucleotide. We confirm that OMI correlates with cellular glycolytic levels across a panel of human breast cell lines using standard assays of cellular rates of glucose uptake and lactate secretion (P < 0.05, r = 0.89). In addition, OMI resolves differences in the basal metabolic activity of untransformed from malignant breast cells (P < 0.05) and between breast cancer subtypes (P< 0.05), defined by estrogen receptor and/or HER2 expression or absence. In vivo OMI is sensitive to metabolic changes induced by inhibition of HER2 with the antibody trastuzumab (herceptin) in HER2-overexpressing human breast cancer xenografts in mice. This response was confirmed with tumor growth curves and stains for Ki67 and cleaved caspase-3. OMI resolved trastuzumab-induced changes in cellular metabolism in vivo as early as 48 hours posttreatment (P < 0.05), whereas fluorodeoxyglucose-positron emission tomography did not resolve any changes with trastuzumab up to 12 days posttreatment (P > 0.05). In addition, OMI resolved cellular subpopulations of differing response in vivo that are critical for investigating drug resistance mechanisms. Importantly, OMI endpoints remained unchanged with trastuzumab treatment in trastuzumabresistant xenografts (P > 0.05). OMI has significant implications for rapid cellular-level assessment of metabolic response to molecular expression and drug action, which would greatly accelerate drug development studies.

UR - http://www.scopus.com/inward/record.url?scp=84886082158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886082158&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-13-0527

DO - 10.1158/0008-5472.CAN-13-0527

M3 - Article

VL - 73

SP - 6164

EP - 6174

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 20

ER -